AstraZeneca’s Imfinzi fails to meet main goals in head and neck cancer study

AstraZeneca Plc’s immunotherapy treatment Imfinzi did not meet the main goals in a late-stage study for advanced head and neck cancer, the London-listed drugmaker said on Friday.

The study, known as “EAGLE”, did not improve overall survival compared with standard chemotherapy in patients with the hard-to-treat disease, the company said.

The results come after AstraZeneca warned last month that its immunotherapy treatment Imfinzi did not meet the main goal of improving survival rates for patients with the most advanced form of lung cancer, putting pressure on its shares.

AstraZeneca has been seen as having a head start in the race for cancer treatments, and Imfinzi was aiming to be the new standard of care in treating early inoperable stage III lung cancer.

“While these results are disappointing, we remain committed to evaluating the potential of Imfinzi and other innovative medicines for patients with head and neck cancer,” said Chief Medical Officer Sean Bohen.

The trial was conducted at 169 centres across 24 countries including the U.S., Europe, South America, Japan, Korea, Taiwan, Israel and Australia, AstraZeneca said.

  • Related Posts

    • Pharma
    • July 9, 2025
    • 81 views
    Nectar to sell API, formulations & menthol biz to Ceph Lifesciences for Rs 1,290 cr

    Nectar Lifesciences Ltd on Tuesday said it will sell its active pharmaceutical ingredients and formulation along with menthol business assets to Ceph Lifesciences Pvt Ltd, for Rs 1,290 crore. The…

    • Pharma
    • July 9, 2025
    • 94 views
    Flush these 17 expired medicines now. India’s top drug regulatory body issues stern warning

    That half-empty bottle of painkillers or expired anxiety pills in your drawer could do more harm than good and Apex drug regulatory body, CDSCO, has said it’s best to flush…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    Nectar to sell API, formulations & menthol biz to Ceph Lifesciences for Rs 1,290 cr

    Nectar to sell API, formulations & menthol biz to Ceph Lifesciences for Rs 1,290 cr

    Flush these 17 expired medicines now. India’s top drug regulatory body issues stern warning

    Flush these 17 expired medicines now. India’s top drug regulatory body issues stern warning

    Sun Pharma confirms the stocks of ‘Levipil 500’ seized by Telangana DCA in raids is spurious

    Sun Pharma confirms the stocks of ‘Levipil 500’ seized by Telangana DCA in raids is spurious

    HC-ordered expert panel for weight loss drug may be set up by mid-July

    HC-ordered expert panel for weight loss drug may be set up by mid-July